2Firsts
Shenzhen, April 2, 2026
Shares of tobacco companies tied to the U.S. nicotine pouch market fell on Wednesday after Reuters reported before the opening bell that the U.S. Food and Drug Administration’s fast-track review of some nicotine pouch applications was facing delays, sharpening investor focus on the regulatory outlook for one of the industry’s key growth categories. Reuters published the report at 7:40 a.m. EDT on April 1, nearly two hours before U.S. markets opened.
Philip Morris International (NYSE: PM) led the decline among the large-cap names exposed to the segment. The stock opened at $161.50 and later fell more than 7% intraday before trimming losses. Barron’s, a financial news outlet, reported PM closed down 4.8% at $157.36 after the Reuters report.
Turning Point Brands (NYSE: TPB) posted the steepest one-day drop among the group. Yahoo Finance historical data show TPB closed at $74.25, down 14.45% on the day, after trading down into the mid-$65 range intraday.
British American Tobacco’s U.S.-listed ADRs (NYSE: BTI) also finished lower. Publicly available historical pricing indicates BTI ended the session at $57.89, down about 1% on the day.
The market reaction underscored the importance of the U.S. nicotine pouch business for major international tobacco groups. Reuters reported that the delayed applications involved leading pouch brands including Philip Morris’ Zyn and BAT’s Velo, while FDA’s nicotine pouch pilot was intended to make PMTA review more efficient.
Further updates on U.S. FDA progress on market authorization for next-generation tobacco products will be available from 2Firsts.
Illustration of selected tobacco stocks on April 1, 2026, showing declines after a premarket media report on possible delays in FDA nicotine pouch reviews. Illustration for reference only. This chart does not represent exact intraday stock price data. ｜Source: Graphic by 2Firsts
相关阅读：
